Table 2.

Compilation of vaccine efficacies estimation for Takeda’s DENVax vaccine phase 3 trial post-vaccination surveillance period part 2 (18 months). Section A shows the vaccine efficacies by serostatus and serotype, and Section B shows the overall vaccine efficacy by serotype. Highlighting problems observed for serotypes 3 (blue) and 4 (grey) are indicated. The raw data used for the Bayesian analysis are available in [10].

Part 2 Efficacy Data of the TAK-003 Phase 3 Trial
section A							section B
	Seropositive at baseline (82.2%)			Seronegative at baseline (74.9%)			Overall (seropositive and seronegative)
							vaccine efficacy
Dengue Serotype	Vaccinated	Control	Estimated vaccine	Vaccinated	Control	Estimated Vaccine	Vaccinated	Control	Estimated vaccine
	($n=9167$)	($n=4589$)	efficacy and 95%	($n=3531$)	($n=1726$)	efficacy and 95%	($n=$ 12,700)	($n=6316$)	efficacy and 95%
	Dengue cases	Dengue cases	Confidence Interval	Dengue cases	Dengue cases	Confidence Interval	Dengue cases	Dengue cases	Confidence Interval
ALL	75	150	$75.8\%$	39	56	$66.1\%$	114	206	$72.5\%$
			[$67.2\%,81.0\%$]			[$48.9\%,77.3\%$]			[$65.6\%,78.1\%$]
$DEN1$	21	37	$71.2\%$	17	25	$66.7\%$	38	62	$69.4\%$
			[$51.8\%,83.3\%$]			[$39.2\%,82.1\%$]			[$54.6\%,79.7\%$]
$DEN2$	7	54	$93.2\%$	1	26	$97.7\%$	8	80	$94.6\%$
			[$91.1\%,97.1\%$]			[$90.7\%,99.7\%$]			[$90.3\%,97.7\%$]
$DEN3$	43	54	$60.3\%$	20	6	$\mathbf{-}\mathbf{59.9}\mathbf{\%}$	63	60	$47.7\%$
			[$40.6\%,73.2\%$]			[$\mathbf{-}\mathbf{328.5}\mathbf{\%}\mathbf{,}\mathbf{31.1}\mathbf{\%}$]			[$25.4\%,63.1\%$]
$DEN4$	4	5	$\mathbf{59.5}\mathbf{\%}$	1	0	inconclusive	5	5	$\mathbf{50.1}\mathbf{\%}$
			[$\mathbf{-}\mathbf{47.2}\mathbf{\%}\mathbf{,}\mathbf{89.4}\mathbf{\%}$]						[$\mathbf{-}\mathbf{72.5}\mathbf{\%}\mathbf{,}\mathbf{85.4}\mathbf{\%}$]